Navigating Late-Phase Clinical Trial Enrollment: Strategies To Stay On Schedule

Late-stage clinical trials (Phases III and IV) represent the most critical hurdle in the drug development lifecycle, where enrollment delays can cost sponsors between $600,000 and $8 million per day. This article examines the mission-critical nature of late-phase recruitment, where the need for thousands of participants meets the challenges of long-term retention and the necessity for diverse representation.

Current data highlights significant disparities in clinical research. This piece outlines how Clinical Operations Executives can bridge such gaps using inclusive messaging and precision targeting. Key strategies discussed include Direct-to-Patient Scaling, Operational Efficiency ad Data-Driven Agility.